Prostate Cancer: To Treat or Not to Treat – That is the Question

PCAP Founder Robert Warren Hess taking a PSA blood test More men with prostate cancer are choosing active surveillance - waiting to see if the tumor grows - instead of having immediate treatment. It's possible that trend will result in more prostate cancer deaths. read more

How Active Surveillance for Prostate Cancer Can Fail

nurse encouraging an annual PSA test How Active Surveillance for Prostate Cancer Can Fail Since the introduction of the prostate specific antigen (PSA) test in the early 1990’s, the medical community has struggled with the issue of over treatment of prostate cancer. The PSA test detects many low-risk prostate cancers that do not immediate treatment.  The treatment protocol for these cancer is called ‘active surveillance (AS).’  The introduction of AS alleviated a good deal of the over treatment but, as the article below shows, men and their doctors need to follow the treatment regimen. When there’s no treatment, it’s easy to forget and the cancer might just turn aggressive. If you are following an active surveillance program, we suggest that you personally track your PSA test with ProstateTracker.  Once you create your ProstateTracker account, you will receive an email reminder every 12 months that it’s time for your next PSA test. This reminder serves as that proverbial ‘string around your finger.’ Read the full article below: Prostate Cancer: ‘Active’ Surveillance Is Often ‘Not’ by: Kate Johnson May 09, 2016 SAN DIEGO, California — Only 1 in 3 men with low-risk prostate cancer receive appropriate follow-up when assigned to active surveillance (AS) of their disease, a new study suggests. The findings […] read more

2013 Genitourinary Cancer Symposium in Orlando, FL – Day 0

Well, I’m checked in at my hotel here in Orlando and I have gone through the three day program and read the Day One issue of the Symposium newspaper – all 28 pages. It’s going to be a great conference with many of the best and brightest minds in the cancer battle at the conference to talk about their research results and successes. The first day and a half of the three-day conference is devoted exclusively to prorate cancer. Which, as a 10-year prostate cancer survivor, I find really encouraging. There is, however, a little (more than a little) irony to be found here already. The Expert Editorial in the Day One conference Daily News is titled “The Role of Active Surveillance for Localized Prostate Cancer: Reducing Overtreatment, Improving Quality of Life.” The article’s central theme once again beats the drum of PSA screening resulting in too much unnecessary treatment. The author notes that “Such stage migration [early detection – my parenthetical insert here] has resulted in the number of diagnoses far outnumbering the number of lethal cases (i.e., over diagnosis of those cancers that would never progress or cause harm to the patient if left untreated). I guess this […] read more